Drug intelligence / Profile preview

LAE106

Development stage: Preclinical
Lead developer: Laekna

Overview

LAE106 is a preclinical drug candidate being developed by Laekna Therapeutics for the treatment of fibrotic diseases, with a particular focus on liver fibrosis. It acts by inhibiting or modulating the transforming growth factor-beta (TGFβ) signaling pathway, which is a central mediator in the development and progression of tissue scarring and fibrogenesis. As of early 2024, the candidate is in the discovery and proof-of-mechanism stage, and Laekna Therapeutics holds global commercial rights for its development. LAE106 is part of a broader portfolio of fibrosis-targeting candidates at Laekna, which also includes LAE104 and LAE105.

Targets

TGFB (GARP–latent transforming growth factor beta 1 complex)

Beyond the preview

Go deeper on LAE106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LAE106.

Explore the full profile